Selected Publications
IGVF Consortium: Deciphering the impact of genomic variation on function. Nature 633: 47-57, Sep 2024.
Riggan KA, Feys R, Kokayi A, Meagher KM, Michie M, Musunuru K, Ormond KE, Schelhaas AJ, Yap JQ, Isasi R, Allyse MA.: Grounded in reality: integrating community values and priorities of end users in human gene editing. Am J Bioeth 24: 43-45, Aug 2024.
Whittaker MN, Musunuru K.: An epigenetic editor to silence genes. Science 384: 1407-1408, Jun 2024.
Lv W, Babu A, Morley MP, Musunuru K, Guerraty MA.: Resource of gene expression data from a multiethnic population cohort of induced pluripotent stem cell-derived cardiomyocytes. Circ Genom Precis Med 17: e004218, Apr 2024.
Brooks DL, Whittaker MN, Said H, Dwivedi G, Qu P, Musunuru K, Ahrens-Nicklas RC, Alameh MG, Wang X.: A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variant. HGG Adv 5: 100253, Jan 2024.
Brooks DL, Whittaker MN, Qu P, Musunuru K, Ahrens-Nicklas RC, Wang X.: Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need. Am J Hum Genet 110: 2003-2014, Dec 2023.
Musunuru K.: Playing the genetic lottery: an interview with Kiran Musunuru. Dis Model Mech 16: dmm050508, Oct 2023.
Whittaker MN, Testa LC, Quigley A, Jindal I, Cortez-Alvarado SV, Qu P, Yang Y, Alameh MG, Musunuru K, Wang X.: Epigenome editing durability varies widely across cardiovascular disease target genes. Arterioscler Thromb Vasc Biol 43: 2075-2077, Oct 2023.
Allyse MA, Meagher KM, Michie M, Isasi R, Ormond KE, Bonhomme N, Bombard Y, Howard H, Musunuru K, Riggan KA, Rubeck S.: Translational justice in human gene editing: bringing end user engagement and policy together. Am J Bioeth 23: 55-58, Jul 2023.
Testa LC, Musunuru K.: Base editing and prime editing: potential therapeutic options for rare and common diseases. BioDrugs 37: 453-462, Jul 2023.
back to top
Last updated: 09/12/2024
The Trustees of the University of Pennsylvania